tradingkey.logo
tradingkey.logo
Search

Treace Medical Concepts Inc

TMCI
Add to Watchlist
4.210USD
-0.020-0.47%
Close 07/02, 13:00ETQuotes delayed by 15 min
272.75MMarket Cap
LossP/E TTM

More Details of Treace Medical Concepts Inc Company

Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.

Treace Medical Concepts Inc Info

Ticker SymbolTMCI
Company nameTreace Medical Concepts Inc
IPO dateApr 23, 2021
CEOTreace (John T)
Number of employees477
Security typeOrdinary Share
Fiscal year-endApr 23
Address100 Palmetto Park Place
CityPONTE VEDRA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code32081
Phone19043735940
Websitehttps://www.treace.com/
Ticker SymbolTMCI
IPO dateApr 23, 2021
CEOTreace (John T)

Company Executives of Treace Medical Concepts Inc

Name
Name/Position
Position
Shareholding
Change
Mr. John K. Bakewell
Mr. John K. Bakewell
Independent Director
Independent Director
546.36K
+5.49%
Dr. Sean F. Scanlan, Ph.D.
Dr. Sean F. Scanlan, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
200.76K
-96.89%
Mr. Scot Michael Elder
Mr. Scot Michael Elder
Chief Legal & Compliance Officer, Corporate Secretary
Chief Legal & Compliance Officer, Corporate Secretary
161.06K
-69.82%
Mr. Lance A. Berry, CPA
Mr. Lance A. Berry, CPA
Independent Director
Independent Director
73.65K
+40.73%
Mr. Gaetano Guglielmino
Mr. Gaetano Guglielmino
Chief Commercial Officer
Chief Commercial Officer
68.65K
--
Mr. Aaron J. Berutti
Mr. Aaron J. Berutti
Senior Vice President - Sales
Senior Vice President - Sales
--
--
Ms. Jane E. Kiernan
Ms. Jane E. Kiernan
Independent Director
Independent Director
--
--
Mr. John T. Treace
Mr. John T. Treace
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Mark L. Hair
Mr. Mark L. Hair
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Lynn Lewis
Ms. Lynn Lewis
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John K. Bakewell
Mr. John K. Bakewell
Independent Director
Independent Director
546.36K
+5.49%
Dr. Sean F. Scanlan, Ph.D.
Dr. Sean F. Scanlan, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
200.76K
-96.89%
Mr. Scot Michael Elder
Mr. Scot Michael Elder
Chief Legal & Compliance Officer, Corporate Secretary
Chief Legal & Compliance Officer, Corporate Secretary
161.06K
-69.82%
Mr. Lance A. Berry, CPA
Mr. Lance A. Berry, CPA
Independent Director
Independent Director
73.65K
+40.73%
Mr. Gaetano Guglielmino
Mr. Gaetano Guglielmino
Chief Commercial Officer
Chief Commercial Officer
68.65K
--
Mr. Aaron J. Berutti
Mr. Aaron J. Berutti
Senior Vice President - Sales
Senior Vice President - Sales
--
--

FAQs

Who are the top five shareholders of Treace Medical Concepts Inc?

The top five shareholders of Treace Medical Concepts Inc are: Mr. John K. Bakewell

How many institutions hold shares of Treace Medical Concepts Inc (TMCI)?

As of 2026Q1, 342 institutions hold shares of Treace Medical Concepts Inc, with a combined market value of approximately 37.97M, accounting for 58.61% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -15683733.00.